NovoCure Limited
NVCRHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NovoCure Limited focuses on Medical Devices services and products. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the. At a $1.84B market cap, NovoCure Limited ranks as a small-cap company within healthcare. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Market Cap
$1.84B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-15.03
EPS (TTM)
$-1.48
EPS (Fwd)
$-1.06
ROE
-50.0%
ROA
-11.1%
Cash
$432.0M
Total Debt
$234.9M
Free CF
$5.1M
52W Change
-0.6%
Annual Financials
Cash vs Debt
NovoCure Limited holds $432.0M in cash against $234.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $5.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -50.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $535.0M (2021) to $655.4M (2025), reflecting a 22% increase over the period.
As with any equity investment, NVCR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NovoCure Limited's trajectory.